The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
Open accessAbstract
BACKGROUND: Idiopathic Pulmonary Fibrosis (IPF) risk has a strong genetic component. Studies have implicated variation at several loci, including telomerase reverse transcriptase (TERT), surfactant genes, and a single nucleotide polymorphism (SNP) at chr11p15, rs35705950 in the intergenic region between TOLLIP and MUC5B. IPF patients with risk alleles at rs35705950 have longer survival from the time of IPF diagnosis than patients homozygous for the non-risk allele, while patients with shorter telomeres have shorter survival times. We hypothesized that rare protein altering variants in genes regulating telomere length are enriched in IPF patients lacking risk alleles at rs35705950. METHODS: Whole genome sequencing of 1,510 patients with sporadic IPF from phase 3 clinical trials and observational studies was used to assess telomere length and identify rare protein altering variants. We separated patients by rs35705950 genotype and assessed rare functional variation in TERT exons and compared genotypes to telomere length and rates of disease progression. FINDINGS: 2⋅9% of patients with an rs35705950 risk allele carried a rare protein-altering variant (RV) in TERT compared to 7⋅3% of non-risk allele carriers (odds ratio [OR] 0⋅40 [95% CI 0⋅24-0⋅66], p=3⋅9 × 10−4). Subsequent analyses identified enrichment of rare protein-altering variants in PARN, RTEL1 and rare variation in TERC in IPF patients compared to non-IPF controls. In total, IPF patients harbored at least one rare variant in TERT, PARN, TERC or RTEL1 more frequently than non-IPF patients from other clinical trials (8⋅57% in IPF vs. 2⋅37% for others p=2⋅44 × 10−8). Patients with a variant in any of the four identified telomerase component genes had 4⋅78%-16⋅10% shorter telomeres and an earlier age of onset (65⋅1 years) than patients without (67⋅1 years; p=0⋅004). Patients with shorter telomeres had more rapid rates of lung function decline in the placebo arms of clinical trials (1⋅7% FVC/kb/year, p=0⋅002). Despite the aforementioned differences, we found pirfenidone demonstrated treatment benefit regardless of telomere length status. INTERPRETATION: Rare protein-altering variants in TERT, PARN, TERC and RTEL1 are enriched in IPF patients compared to non-IPF controls, and, in the case of TERT, particularly in those not carrying a risk allele at the rs35705950 locus, suggesting that there are multiple genetic factors underlying sporadic IPF that may implicate distinct mechanisms of pathogenesis and rates of progression. TRIAL REGISTRATION: NCT00287716, NCT01366209, NCT00075998, NCT01872689.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Self-citationTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357
Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq
Treutlein, B., Brownfield, D. G., Wu, A. R., Neff, N. F., Mantalas, G. L., Espinoza, F. H., Desai, T. J., Krasnow, M. A., & Quake, S. R. (2014) · Nature · doi:10.1038/nature13173 · Cited by 1,342
A Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial Lung Disease
Nogee, L. M., Dunbar, A. E., Wert, S. E., Askin, F., Hamvas, A., & Whitsett, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440805 · Cited by 929
Cited by
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Self-citationDeterminants of telomere length across human tissues
Demanelis, K., Jasmine, F., Chen, L. S., Chernoff, M., Tong, L., Delgado, D., Zhang, C., Shinkle, J., Sabarinathan, M., Lin, H., et al. (2020) · Science · doi:10.1126/science.aaz6876 · Cited by 515
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
Allen, R. J., Guillen-Guio, B., Oldham, J. M., Ma, S.-F., Dressen, A., Paynton, M. L., Kraven, L. M., Obeidat, M., Li, X., Ng, M., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201905-1017oc · Cited by 329
Self-citationContributions of alveolar epithelial cell quality control to pulmonary fibrosis
Katzen, J., & Beers, M. F. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139519 · Cited by 287
Metadata
- Authors
- Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R., Brauer, M. J., Hunkapiller, J., Reeder, J., Mukhyala, K., Cuenco, K., Tom, J., Cowgill, A., Vogel, J., Forrest, W. F., Collard, H. R., Wolters, P. J., Kropski, J. A., Lancaster, L. H., Blackwell, T. S., Arron, J. R., & Yaspan, B. L.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 6
- Issue
- 8
- Pages
- 603-614
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2807259602
- Cited by
- 196
- References
- 24
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30135-8
- The paper
- Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R., Brauer, M. J., Hunkapiller, J., Reeder, J., Mukhyala, K., Cuenco, K., Tom, J., Cowgill, A., Vogel, J., Forrest, W. F., Collard, H. R., Wolters, P. J., Kropski, J. A., . . . Yaspan, B. L. (2018). Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30135-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.